In Japan, Schering-Plough has received marketing approval for an additional indication for Peg-Intron (peginterferon alfa-2b powder for injection) in combination with Rebetol (ribavirin) - for the treatment of chronic hepatitis C in adult patients other than those with genotype 1 virus and high viral load.
The expanded use represents around 40% of the patient population in Japan, where this combination was cleared in October 2004 for treating patients with genotype 1 virus and high viral load.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze